# A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)

> **NCT07704892** · PHASE3 · RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 380 (estimated)

## Conditions studied

- Metabolic Dysfunction-associated Steatohepatitis

## Interventions

- **DRUG:** Efimosfermin alfa
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07704892
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-22
- **Primary completion:** 2030-10-16
- **Final completion:** 2033-12-08
- **Target enrollment:** 380 (ESTIMATED)
- **Last updated:** 2026-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07704892

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07704892, "A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07704892. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*